| S.No. | Code | Description |
| 1 |
B053
| ACID PHOSPHATASE, TOTAL |
| 3 |
B148
| KAPPA / LAMBDA LIGHT CHAINS, FREE, SERUM |
| 4 |
E005
| IMMUNOFIXATION ELECTROPHORESIS (IFE), SERUM |
| 5 |
E006
| IMMUNOFIXATION ELECTROPHORESIS, 24-HOUR URINE |
| 6 |
E012
| IMMUNOGLOBULIN IgD & IgE TYPING, SERUM < |
| 7 |
E013
| IMMUNOGLOBULIN IgD & IgE TYPING,URINE |
| 8 |
F001
| AFP (ALPHA FETOPROTEIN), TUMOR MARKER |
| 9 |
F002
| HCG, BETA, TOTAL, QUANTITATIVE, TUMOR MARKER |
| 10 |
F003
| CEA; CARCINO EMBRYONIC ANTIGEN < |
| 11 |
F007
| CA 125 ; OVARIAN CANCER MARKER < |
| 12 |
F008
| CA 19.9; PANCREATIC CANCER MARKER |
| 13 |
F009
| CA 72.4; GASTRIC CANCER MARKER < |
| 14 |
F010
| CA 15.3; BREAST CANCER MARKER |
| 15 |
F012
| THYROGLOBULIN; Tg Cancer Marker |
| 16 |
F014
| PSA ( PROSTATE - SPECIFIC ANTIGEN), TOTAL Prostatic Cancer Marker. |
| 17 |
F015
| (CA) CYFRA 21-1; LUNG CANCER MARKER |
| 18 |
F017
| PSA ( PROSTATE - SPECIFIC ANTIGEN), FREE Prostatic Cancer Marker. |
| 19 |
F019
| NEURON SPECIFIC ENOLASE (NSE), SERUM |
| 20 |
F022
| INHIBIN A, REPRODUCTIVE MARKER < |
| 21 |
H 153
| CD 33 ( Myeloid cell marker) |
| 22 |
H135
| CD 2 (Pan T cell marker) |
| 23 |
H136
| CD 3( Pan T cell marker) |
| 24 |
H138
| CD 5 ( T cell / B cell subset) < |
| 25 |
H139
| CD 7 (Pan T cell/early myeloid cell marker) |
| 26 |
H141
| CD 10 / CALLA (Prognostic ALL marker) < |
| 27 |
H142
| CD 11c (Hairy cell / NHL marker) |
| 28 |
H143
| CD 13 (Myeloid cell marker) |
| 29 |
H144
| CD 14 (Monocytic cell marker) |
| 30 |
H145
| CD 15 (Myeloid cell marker) |
| 31 |
H147
| CD 19 (Pan B cell marker) |
| 32 |
H148
| CD 20 ( Pan B cell marker) |
| 33 |
H149
| CD 22 (Pan B cell marker) |
| 34 |
H150
| CD 23 (CLL segregation marker) < |
| 35 |
H151
| CD 25 (Hairy cell / NHL marker) |
| 36 |
H154
| CD 34 (Precursor cell marker) |
| 37 |
H155
| CD 38 (Plasma cell /prognostic CLL marker) |
| 38 |
H156
| CD 42a (Megakaryocytic cell marker) |
| 39 |
H157
| CD 45/ LCA (Leukocyte common antigen ) < |
| 40 |
H158
| CD 61 (Megakaryocytic cell marker) |
| 41 |
H160
| FMC-7 (Prognostic CLL / NHLmarker) |
| 42 |
H161
| Glycophorin (Erythroid marker) < |
| 43 |
H162
| HLA DR ( Activation marker) |
| 44 |
H163
| IgA Heavy Chain Cytoplasmic (Clonal restriction/B cell maturity marker ) |
| 45 |
H164
| IgA Heavy Chain Surface (Clonal restriction/B cell maturity marker) |
| 46 |
H165
| IgD Heavy Chain Cytoplasmic (Clonal restriction / B cell maturity marker ) |
| 47 |
H166
| IgD Heavy Chain Surface (Clonal restriction / B cell maturity marker ) |
| 48 |
H167
| IgG Heavy Chain Cytoplasmic (Clonal restriction / B cell maturity marker ) |
| 49 |
H168
| IgG Heavy Chain Surface (Clonal restriction/B cell maturity marker ) |
| 50 |
H169
| IgM Heavy Chain Cytoplasmic (Pre B cell ALL prognostic / Clonal restriction marker ) |
| 51 |
H170
| IgM Heavy Chain Surface (Clonal restriction / B cell maturity marker ) |
| 52 |
H171
| Kappa & Lambda Light chains (Clonal restriction / B cell maturity marker) |
| 53 |
H172
| TdT (Precursor cell marker) |
| 54 |
H181
| CD103 (Hairy cell marker) |
| 55 |
H203
| CD MPO (Myeloid cell marker) |
| 56 |
H222
| CD 79a (B Lymphoid cell marker) |
| 57 |
H223
| CD 117 (Myeloid marker) |
| 59 |
J006
| CYTOLOGY, GENITAL, FEMALE; PAP SMEAR, FEMALE |
| 60 |
J008
| CYTOLOGY, CONSULTATION - SECOND OPINION |
| 61 |
J009
| ESTROGEN RECEPTOR; ER |
| 64 |
J010
| PR ('Progesterone Receptor) |
| 65 |
J011
| CYTOLOGY (PAP SMEAR) EXAMINATION |
| 66 |
J017
| CYTOKERATIN (Pancytokeratin) |
| 67 |
J018
| DESMIN |
| 70 |
J031
| S100 |
| 73 |
J034
| GFAP (Glial Fibrilliary Acidic Protein) |
| 74 |
J036
| NSE (Neuron Specific Enolase) |
| 75 |
J037
| CD45 Ro (Pan T) |
| 89 |
J076
| ACTIN (Smooth Muscle Actin ) |
| 90 |
J077
| EGFR (Epidermal Growth Factor Receptor) |
| 91 |
J093
| PSA (Prostate Specific Antigen) |
| 92 |
J094
| bcl-2 |
| 107 |
J117
| HISTOPATHOLOGY, BIOPSY, SKIN |
| 108 |
J118
| HISTOPATHOLOGY, BIOPSY, BONE |
| 109 |
J119
| HISTO/CYTOPATHOLOGY, SLIDE(S) / BLOCK(S), ISSUE |
| 110 |
J130
| CYCLIN D1 |
| 117 |
R061
| BETA - 2 - MICROGLOBULIN, SERUM |
| 118 |
R062
| CALCITONIN |
| 120 |
R098
| CHROMOGRANIN A; CGA |
| 123 |
RW067
| EPSTEIN-BARR VIRUS, ANTIBODY TO EARLY ANTIGEN (D), IgG |
| 124 |
RW119
| LEGIONELLA PNEUMOPHILA IgG, IFA |
| 125 |
RW148
| PLATELET ANTIBODY, INDIRECT, IgG |
| 126 |
RW169
| RISTOCETIN COFACTOR |
| 128 |
RW188
| TRIMIPRAMINE |
| 132 |
U006
| VMA (VANILMANDELIC ACID), 24-HOUR URINE |
| 133 |
U024
| CATECHOLAMINES, 24-HOUR URINE Includes Epinephrine, Norepinephrine and Dopamine |
| 134 |
U030
| VMA (VANILMANDELIC ACID) , RANDOM URINE |
| 135 |
U034
| 5-HIAA (5-HYDROXYINDOLEACETIC ACID), 24-HOUR URINE |
| 136 |
U035
| METANEPHRINES, 24-HOUR URINE *Metanephrine * Normetanephrine |
| 137 |
U036
| HOMOVANILLIC ACID (HVA), 24-HOUR URINE < |
| 138 |
U038
| 5-HIAA (5-HYDROXYINDOLEACETIC ACID), RANDOM URINE |
| 139 |
U041
| BETA-2-MICROGLOBULIN, RANDOM URINE |
| 140 |
U043
| CATECHOLAMINES, RANDOM URINE Includes epinephrine, norepinephrine and dopamine |
| 141 |
U049
| HOMOVANILLIC ACID (HVA), RANDOM URINE |
| 142 |
U052
| METANEPHRINES, RANDOM URINE *Metanephrine * Normetanephrine |
| 143 |
U079
| KAPPA / LAMBDA LIGHT CHAINS, FREE, URINE |
| 144 |
XX001
| BCR / ABL or Philadelphia translocation |
| 145 |
XX002
| t (15;17) or LSI PML/RARA |
| 146 |
XX003
| t (8;21) or LSI ETO/AMLI |
| 147 |
XX004
| inv (16) or LSI CBFB |
| 150 |
XX007
| 11q 23 or LSI MLL gene breakapart |
| 151 |
XX008
| t (12;21) or LSI TEL/AMLI |
| 152 |
XX009
| 14q 32.3 or LSI IGH gene breakapart |
| 153 |
XX011
| Breast Cancer Her-2/neu oncogene amplification |
| 154 |
XX012
| Oncology EGFR gene amplification |
| 155 |
XX013
| Oncology 1p and 19q codeletion < |
| 156 |
XX022
| MDS Panel - Chromosomes 5q, 7q, 8q & 20q |
| 157 |
XX023
| CLL Panel - DLEU (13q 14), p53(17p13), ATM (11q22), GLI (12q13), 6q21 and C-myc(8q24) |
| 158 |
XX024
| Bladder cancer recurrence : Chromosomes 3,7, 17 and p16 gene on chromosomes 9 |
| 159 |
Z046
| CALCITONIN STIMULATION BY CALCIUM PENTAGASTRIN |
| 160 |
Z052
| CATECHOLAMINES PLASMA, SUPPRESSION BY CLONIDINE |
| 161 |
Z061
| GASTRIN STIMULATION BY SECRETIN |
| 162 |
Z118
| CATECHOLAMINES & VMA, 24-HOUR URINE |
| 163 |
Z144
| PHEOCHROMOCYTOMA PROFILE, 24-HOUR URINE *VMA *Metanephrines *Catecholamines |
| 164 |
Z149
| LYMPHOMA DIAGNOSTIC PANEL *CD2 *CD 3 *CD4 *CD5 *CD8 *CD10* CD11* CD19 *CD20 * CD22 *CD23 *CD33 * CD45* CD79a* Surface |
| 165 |
Z150
| LEUKEMIA DIAGNOSTIC PANEL: ACUTE LEUKEMIAS *CD19*CD22*CD79a cyto *CD10 *CD2 *CD3 cyto* CD5* CD7* CD13* CD14* CD 15 |
| 166 |
Z151
| LEUKEMIA / LYMPHOMA DIAGNOSTIC PANEL: CHRONIC LYMPHOPROLIFERATIVE DISORDERS: CD2* CD3* CD4* CD5* CD8* CD10* CD11c* |
| 167 |
Z154
| LEUKEMIA MONITORING PANEL: HAIRY CELL *CD5 *CD11c* CD19 *CD20 *CD25 * CD 45 * CD 103 *Kappa/ Lambda* FMC-7 *Heavy |
| 168 |
Z184
| NEUROBLASTOMA PROFILE, 24-HOUR URINE *Vanil Mandelic Acid (VMA) *Homovanilic Acid (HVA) |
| 169 |
Z186
| PROTEIN ELECTROPHORESIS & IFE, SERUM Includes total protein, electrophoretic fractions, densitometric tracing and |
| 170 |
Z221
| IMMUNOHISTOCHEMISTRY, SARCOMA TYPING PANEL *Desmin * Vimentin *S100 *Smooth Muscle Actin * CD31 * CD34 |
| 171 |
Z240
| BREAST CANCER PANEL 1 * ER (Estrogen Receptor) *PR (Progesterone Receptor) Includes pathologist review for presence |
| 172 |
Z242
| BREAST CANCER PANEL 2 *ER*PR*Cathepsin D. Includes pathologist review for presence of malignant cells. |
| 173 |
Z262
| PSA PROFILE *PSA, Total *PSA, Free *Free/Total Percent
Prostatic Cancer Markers. |
| 174 |
Z269
| LEUKEMIA DIAGNOSTIC PANEL: AML CHARACTERIZATION CD 3 *CD7* CD13* CD14* CD15* CD19* CD33* CD34* CD 42 a* CD45* CD
61 * CD 117*HLA DR* MPO * Glycophorin A.
If required: CD4, CD36, CD64, CD123 |
| 175 |
Z281
| LEUKEMIA DIAGNOSTIC PANEL:ALL CHARACTERIZATION *CD3 *CD7 *CD10 *CD19 *CD22 *CD33 *CD34 *CD45 *Cyto IgM* CD79a cyto |
| 176 |
Z282
| LEUKEMIA DIAGNOSTIC PANEL;CLL/HCL/SLL (BASIC) *CD5 * CD7 * CD 10 *CD11c *CD19 *CD20 *CD23 *CD25 *CD 38 *CD45 *FMC 7* |
| 177 |
Z293
| BREAST CANCER PANEL 3 *ER*PR*c-erb B2 (HER-2 neu). Includes Pathologist review for presence of malignant cells. |
| 178 |
Z306
| CA 27.29 & CA 15.3 BREAST CANCER MARKERS PANEL |
| 179 |
Z360
| IMMUNOHISTOCHEMISTRY, CARCINOMA VS LYMPHOMA PANEL *LCA*CK |
| 180 |
Z361
| IMMUNOHISTOCHEMISTRY, HODGKINS VS NON HODGKINS LYMPHOMA PANEL *CD3 * CD15 * CD20 * CD30 * EMA |
| 181 |
Z362
| IMMUNOHISTOCHEMISTRY, FOLLICULAR LYMPHOMA VS REACTIVE HYPERPLASIA PANEL *CD3 * CD20 * bcl-2 |
| 182 |
Z363
| IMMUNOHISTOCHEMISTRY, DIFFUSE SMALL CELL LYMPHOMA PANEL *CD3 *CD5 *CD10 *CD20 *CD23 |
| 183 |
Z364
| IMMUNOHISTOCHEMISTRY, DIFFUSE LARGE CELL LYMPHOMA PANEL *CD3 *CD10 *CD20 * CD30 * CD79a |
| 184 |
Z387
| BREAST METASTATIC MARKER * ER (Estrogen Receptor) *PR (Progesterone Receptor) *CA 15.3. Includes pathologist review |
| 185 |
Z388
| BREAST MONITOR PANEL * CA 15.3 * CEA |
| 186 |
Z496
| CD 55 & 59 (PNH markers) |
